Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUOTED. July 6, 2018. Gerard Criner.

Executive Summary

Almost a decade after US FDA first rejected it, the agency approved Pulmonx Corp.'s Zephyr endobronchial valve system based on clinical results from the company's Liberate study and two other multicenter randomized control trials. See what Liberate lead investigator Gerard Criner said about the device here.

"Zephyr valves are a major step forward in treating severe emphysema patients who consistently feel short of breath despite all the medications we can offer." –Gerard Criner, chair and professor of thoracic medicine and surgery, Lewis Katz School of Medicine at Temple University

Click here for a free trial of Medtech Insight

Advertisement

Related Content

Pulmonx's FDA Nod: First To US Market With Endobronchial Valve System

Topics

Advertisement
UsernamePublicRestriction

Register

MT122917

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel